Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Boston Scientific’s Taxus Liberte stent receives approval for Canadian market

Boston Scientific : 17 April, 2008  (New Product)
Boston Scientific has received approval for the sale of its Taxus Liberte paclitaxel-eluting coronary stent system in Canada.
The company reported that Health Canada's Therapeutic Products Directorate (TPD), the authority that regulates pharmaceutical drugs and medical devices, has approved its use. Boston Scientific plans to launch the product immediately in Canada.

'The Taxus Liberte Stent is a major advance in Stent development and raises the bar for drug-eluting Stent systems,' said Serge Doucet, MD, cathlab director at the Montreal Heart Institute. 'It offers enhanced ability to conform to the vessel wall and deliver across some of the most challenging lesions. This innovation is welcome news for interventional cardiologists and patients in Canada who suffer from coronary artery disease.'

'This Stent is designed specifically for improved drug elution and deliverability,' said David McFaul, Boston Scientific senior vice president, international. 'Coupled with our proven paclitaxel-eluting technology, Taxus Liberte provides physicians with next-generation performance. We are delighted that Canadian physicians and patients can now benefit from this highly advanced technology for the treatment of coronary artery disease.'

Currently the leading drug-eluting stents worldwide, Taxus Stent Systems have been evaluated by the industry's most extensive randomised, controlled clinical trial programme, as well as studied in more than 35,000 real-world patients enrolled in post-approval registries. To date, approximately four million Taxus Stents have been implanted worldwide.

The Taxus Liberte Stent has previously been approved for sale in Europe and other international markets and is currently awaiting approval by the US Food and Drug Administration and is not available for sale in the USA.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo